在儿科霍奇金淋巴瘤中,放射治疗的响应适应降级
Mohamed Abdelwahed Bayoumi1, Omar Shawky Arafah1, Ehab Mohamed Khalil2
1Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo city, Egypt.
Leukemia & lymphoma
|March 14, 2026
概括
在小儿霍奇金治疗中最大限度地减少放射治疗 (RT).
科学领域:
- 儿科瘤学 儿科瘤学
- 辐射瘤学 辐射瘤学
- 临床研究 临床研究
背景情况:
- 儿科霍奇金淋巴瘤 (PHL) 的治愈率很高.
- 重点是减少治疗的长期副作用,特别是放射治疗 (RT).
- 响应适应疗法旨在根据早期治疗反应量身定制治疗强度.
研究的目的:
- 根据早期反应,评估在小儿霍奇金淋巴瘤患者中省略或最小化RT的影响.
- 为了比较响应适应治疗组与接受标准RT的历史对照组的结果.
主要方法:
- 用响应适应方法治疗的小儿霍奇金淋巴瘤患者的回顾性分析 (研究组).
- 与接受化疗和涉及野外放射治疗的历史队列进行比较.
- 将患者分为快速早期反应 (RER) 和缓慢早期反应 (SER) 的两组.
主要成果:
- 两组RER患者实现了100%的整体存活率 (OS) 和可比的无事件存活率 (EFS).
- 两组SER患者的OS和EFS表现相似.
- 减少或省略RT并没有对RER或SER组的结果产生负面影响.
结论:
- 省略RT可能是安全的小儿霍奇金淋巴瘤患者与RER.
- 尽量减少SER患者的RT与劣质结果无关.
- 可以考虑响应适应的RT策略,以减少小儿霍奇金淋巴瘤的治疗负担.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
351
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drug Dosing: Infants and Children
682
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682


